StocksMedium•5 November 2026•
1 min read
China Approves Johnson & Johnson's Macitentan for Pediatric PAH
Key Facts
1China's National Medical Products Administration approved Johnson & Johnson's macitentan dispersible tablets.
2The drug is indicated for the treatment of pediatric pulmonary arterial hypertension.
China's National Medical Products Administration approved Johnson & Johnson's macitentan dispersible tablets. Benzinga reported that the drug is indicated for the treatment of pediatric pulmonary arterial hypertension, expanding the company's pharmaceutical portfolio within the Chinese market.
Johnson & Johnson (JNJ) was trading at $275.35 on November 5, 2026, reaching a session high of $281.92 and a low of $275. This regulatory milestone follows recent Chinese economic data showing service sector expansion, with the Services PMI recorded at 50.8 on November 4, 2026.